CN114144176A - 用于抑制fgfr4的化合物 - Google Patents

用于抑制fgfr4的化合物 Download PDF

Info

Publication number
CN114144176A
CN114144176A CN202080052789.9A CN202080052789A CN114144176A CN 114144176 A CN114144176 A CN 114144176A CN 202080052789 A CN202080052789 A CN 202080052789A CN 114144176 A CN114144176 A CN 114144176A
Authority
CN
China
Prior art keywords
group
alkyl
pharmaceutically acceptable
acceptable salt
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080052789.9A
Other languages
English (en)
Chinese (zh)
Inventor
徐英姿
F·A·罗曼罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tuozhen Pharmaceutical Co
Original Assignee
Tuozhen Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuozhen Pharmaceutical Co filed Critical Tuozhen Pharmaceutical Co
Publication of CN114144176A publication Critical patent/CN114144176A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080052789.9A 2019-06-21 2020-06-18 用于抑制fgfr4的化合物 Pending CN114144176A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864883P 2019-06-21 2019-06-21
US62/864,883 2019-06-21
PCT/US2020/038541 WO2020257527A1 (en) 2019-06-21 2020-06-18 Compounds for inhibiting fgfr4

Publications (1)

Publication Number Publication Date
CN114144176A true CN114144176A (zh) 2022-03-04

Family

ID=74037325

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080052789.9A Pending CN114144176A (zh) 2019-06-21 2020-06-18 用于抑制fgfr4的化合物

Country Status (7)

Country Link
US (1) US20220362245A1 (enExample)
EP (1) EP3986405A4 (enExample)
JP (1) JP2022537415A (enExample)
CN (1) CN114144176A (enExample)
AU (1) AU2020298246A1 (enExample)
CA (1) CA3144366A1 (enExample)
WO (1) WO2020257527A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835640A (zh) * 2022-05-24 2022-08-02 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003400B (zh) * 2021-10-22 2025-05-02 暨南大学 2-甲酰基四氢萘啶类化合物及其药用组合物和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683188A (zh) * 2013-10-25 2016-06-15 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
WO2017164705A1 (ko) * 2016-03-24 2017-09-28 재단법인 대구경북첨단의료산업진흥재단 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물
WO2017198149A1 (zh) * 2016-05-20 2017-11-23 江苏豪森药业集团有限公司 Fgfr4抑制剂、其制备方法和应用
CN107406448A (zh) * 2015-03-25 2017-11-28 诺华股份有限公司 N‑(5‑氰基‑4‑((2‑甲氧乙基)氨基)吡啶‑2‑基)‑7‑甲酰基‑6‑((4‑甲基‑2‑氧代哌嗪‑1‑基)甲基)‑3,4‑二氢‑1,8‑萘啶‑1(2h)‑甲酰胺的颗粒
WO2018028664A1 (zh) * 2016-08-12 2018-02-15 江苏豪森药业集团有限公司 Fgfr4抑制剂及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108341815A (zh) * 2017-01-25 2018-07-31 上海喆邺生物科技有限公司 一种抑制激酶化合物及其用途
CN109745321B (zh) * 2017-11-08 2022-04-29 上海翰森生物医药科技有限公司 包含fgfr4抑制剂的药物组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683188A (zh) * 2013-10-25 2016-06-15 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN107406448A (zh) * 2015-03-25 2017-11-28 诺华股份有限公司 N‑(5‑氰基‑4‑((2‑甲氧乙基)氨基)吡啶‑2‑基)‑7‑甲酰基‑6‑((4‑甲基‑2‑氧代哌嗪‑1‑基)甲基)‑3,4‑二氢‑1,8‑萘啶‑1(2h)‑甲酰胺的颗粒
WO2017164705A1 (ko) * 2016-03-24 2017-09-28 재단법인 대구경북첨단의료산업진흥재단 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물
WO2017198149A1 (zh) * 2016-05-20 2017-11-23 江苏豪森药业集团有限公司 Fgfr4抑制剂、其制备方法和应用
WO2018028664A1 (zh) * 2016-08-12 2018-02-15 江苏豪森药业集团有限公司 Fgfr4抑制剂及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KNOEPFEL, THOMAS 等: "2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4", 《ACS MEDICINAL CHEMISTRY LETTERS》, vol. 9, no. 3, pages 215 - 220, XP055584418, DOI: 10.1021/acsmedchemlett.7b00485 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835640A (zh) * 2022-05-24 2022-08-02 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用

Also Published As

Publication number Publication date
EP3986405A1 (en) 2022-04-27
AU2020298246A1 (en) 2022-01-27
EP3986405A4 (en) 2023-06-14
JP2022537415A (ja) 2022-08-25
US20220362245A1 (en) 2022-11-17
WO2020257527A1 (en) 2020-12-24
CA3144366A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
KR102204804B1 (ko) 디히드로피라졸 gpr40 조절제
CN115835866B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
CN112469720B (zh) 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN115955979B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
JP7372686B2 (ja) Ｔｒｋ阻害剤としてのヘテロ環化合物
BR112014010177B1 (pt) Composto, composição farmacêutica, e, uso de um composto
EP3468956A1 (en) 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
EP4423068B1 (en) Rxfp1 agonists
KR102150739B1 (ko) 카르바메이트/우레아 유도체
BR112013021566B1 (pt) composto, composição farmacêutica e uso de um composto de fórmula (i)
BR112018014675B1 (pt) Derivados de cianoindolina substituída como inibidores de nik e composição farmacêutica que os compreende
JP2022548250A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
CN114144176A (zh) 用于抑制fgfr4的化合物
WO2011019060A1 (ja) ヘッジホッグシグナル阻害剤
US20250059206A1 (en) Fused ring compound acting as shp2 inhibitor
BR112020010171A2 (pt) derivados de piridinona, seu uso como inibidores seletivos de alk-2, composição farmacêutica, combinação, e kit
TW202100514A (zh) 芳香族衍生物其製備方法和醫學用途
CN115515959B (zh) 用作tead结合剂的三环杂环
EP4293029A1 (en) Azaheteroaryl compound, preparation method therefor, and application thereof
KR20170095243A (ko) Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171126A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN117396463A (zh) 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法和含有其作为活性成分的药物组合物
CA3180661A1 (en) Cycloalkyl pyrimidines as ferroportin inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220304